Yan Guo

Dr. Yan Guo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
YGYan Guo
Yan Guo
HYHaodi Yue
Haodi Yue
LZLindong Zhang
Lindong Zhang
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.

18 January 2024 in Heliyon
Verified
Journal Article
Open access
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
ZZZidi Zhang
Zidi Zhang
YGYan Guo
Yan Guo
XLXueling Lou
Xueling Lou
LZLindong Zhang
Lindong Zhang
The Ubiquitin Conjugating Enzyme E2 S (UBE2S), was initially identified as a crucial member in controlling substrate ubiquitination during the late promotion of the complex's function. In recent years, UBE2S has emerged as a significant epigenetic modification in various diseases, including myocardial ischemia, viral hepatitis, and notably, cancer. Mounting evidence suggests that UBE2S plays a pivotal role in several human malignancies including breast cancer, lung cancer, hepatocellular carcinoma and etc. However, a comprehensive review of UBE2S in human tumor research remains absent. Therefore, this paper aims to fill this gap. This review provides a comprehensive analysis of the structural characteristics of UBE2S and its potential utility as a biomarker in diverse cancer types. Additionally, the role of UBE2S in conferring resistance to tumor treatment is examined. The findings suggest that UBE2S holds promise as a diagnostic and therapeutic target in multiple malignancies, thereby offering novel avenues for cancer therapy.

5 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
TRTonghui Ren
Tonghui Ren
LSLingqi Sun
Lingqi Sun
YZYichen Zheng
Yichen Zheng
YJYixuan Jiang
Yixuan Jiang
YGYan Guo
Yan Guo
JMJi Ma
Ji Ma
The tumor microenvironment (TME) plays a crucial regulatory role in the initiation and progression of tumors. Mechanical forces in the TME, such as matrix stiffness, solid stress, fluid shear stress, and microstructural changes, can regulate the activity, migration, and proliferation of immune cells through mechanotransduction pathways, thereby affecting the growth and immune evasion of tumor cells. However, the precise mechanisms by which mechanical forces regulate immune cells and their impact on immunotherapy are not yet fully understood. This review aims to explore how mechanical forces in the TME regulate T cells, natural killer cells, tumor-associated macrophages, B cells, neutrophils, and dendritic cells, and influence immunotherapy. Additionally, this review emphasizes the temporal effects of mechanical forces on immune cells during tumor progression and highlights the need to investigate the interactions of different mechanical forces in the TME and their combined effects on immune cells. These insights can provide a theoretical basis and research directions for optimizing future tumor treatment strategies based on mechanical regulation.

20 January 2024 in Heliyon
Verified
Journal Article
Open access
LZLindong Zhang
Lindong Zhang
JWJialin Wang
Jialin Wang
YGYan Guo
Yan Guo
HYHaodi Yue
Haodi Yue
MZMengjun Zhang
Mengjun Zhang
Adequate prognostic prediction of Uterine Corpus Endometrial Carcinoma (UCEC) is crucial for informing clinical decision-making. However, there is a scarcity of research on the utilization of a nomogram prognostic evaluation model that incorporates pyroptosis-related genes (PRGs) in UCEC. By analyzing data from UCEC patients in the TCGA database, four PRGs associated with prognosis were identified. Subsequently, a “risk score” was developed using these four PRGs and LASSO. Ordinary and web-based dynamic nomogram prognosis prediction models were constructed. The discrimination, calibration, clinical benefit, and promotional value of the selected GPX4 were validated. The expression level of GPX4 in UCEC cell lines was subsequently verified. The effects of GPX4 knock-down on the malignant biological behavior of UCEC cells were assessed. Four key PRGs and a “risk score” were identified, with the “risk score” calculated as (−0.4323) * GPX4 + (0.2385) * GSDME + (0.0525) * NLRP2 + (−0.3299) * NOD2. The nomogram prognosis prediction model, incorporating the “risk score,” “age,” and “FIGO stage,” demonstrated moderate predictive performance (AUC >0.7), good calibration, and clinical significance for 1, 3, and 5-year survival. The web-based dynamic nomogram demonstrated significant promotional value (https://shibaolu.shinyapps.io/DynamicNomogramForUCEC/). UCEC cells exhibited abnormally elevated expression of GPX4, and the knockdown of GPX4 effectively suppressed malignant biological activities, including proliferation and migration, while inducing apoptosis. The findings from tumorigenic experiments conducted on nude mice further validated the results obtained from cellular experiments. Following validation, the nomogram prognosis prediction model, which relies on four pivotal PRGs, demonstrated a high degree of accuracy in forecasting the precise probability of prognosis for patients with UCEC. Additionally, the web-based dynamic nomogram exhibited considerable potential for promotion. Notably, the key gene GPX4 exhibited characteristics of a potential oncogene in UCEC, as it facilitated malignant biological behavior and impeded apoptosis.

13 December 2025 in Cellular Signalling
Verified
Journal Article
Closed access
HYHaodi Yue
Haodi Yue
MZMengjun Zhang
Mengjun Zhang
JLJingyi Lu
Jingyi Lu
ZZZidi Zhang
Zidi Zhang
JWJialin Wang
Jialin Wang
YGYan Guo
Yan Guo